Neurocrine Biosciences NBIX Market capitalization
Market capitalization at other companies
Other financials
Where this comes from
Computed from the period-end share price: $13.22B.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's market capitalization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's market capitalization?
- Neurocrine Biosciences (NBIX) reported market capitalization of $13.22B in Q1 2026.
- How has Neurocrine Biosciences's market capitalization changed year-over-year?
- Neurocrine Biosciences's market capitalization increased by 19.9% year-over-year, from $11.03B to $13.22B.
- What is the long-term trend for Neurocrine Biosciences's market capitalization?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's market capitalization has grown at a 9.8% compound annual growth rate (CAGR), from $35.64B to $51.78B.
- What does market capitalization mean?
- What the stock market says the company's equity is worth.
- How do you interpret market capitalization?
- A size and market-sentiment gauge, not a quality measure — interpret through valuation ratios (P/E, P/S) that relate it to fundamentals.
- How does market capitalization compare across companies?
- Comparable across companies as a size class; the input to every equity-price valuation multiple.